Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
Bone Marrow Examination
/ methods
Cell Separation
/ methods
Centrifugation
/ methods
Centrifugation, Density Gradient
/ methods
Clone Cells
DNA Primers
DNA, Neoplasm
/ analysis
Ficoll
Gene Rearrangement
Genes, Immunoglobulin
Humans
Leukocytes, Mononuclear
Multiple Myeloma
/ genetics
Neoplasm, Residual
Neoplastic Stem Cells
Plasma Cells
Real-Time Polymerase Chain Reaction
Sensitivity and Specificity
Specimen Handling
ASO RQ-PCR
Minimal residual disease
bone marrow buffy coat
ficolled bone marrow
multiple myeloma
red cell lysis
sample preparation
sensitivity
Journal
Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Buffy coat and ficoll of bone marrow (BM) are viable options for the study of minimal residual disease (MRD) in multiple myeloma (MM). As yet, there is no data about the superiority of either sample types. Herein, we aimed to address this issue. Forty pairs of ficolled BMs and BM buffy coats of 19 MM patients were studied for MRD by allele-specific oligonucleotide real-time quantitative PCR, with patient-specific primers/probes whenever appropriate. There were 41 pairs of MRD data for comparison analysis due to one patient with biclonal disease. MRD levels in ficolls and buffy coats were highly concordant ( Taken together, ficolled BM is more sensitive than BM buffy coat for MRD detection in MM, hence should be recommended.
Identifiants
pubmed: 31280705
doi: 10.1080/16078454.2019.1637574
doi:
Substances chimiques
DNA Primers
0
DNA, Neoplasm
0
Ficoll
25702-74-3
Types de publication
Comparative Study
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM